药石科技(300725) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥499,325,806.76, representing a 30.36% increase year-over-year[6] - Net profit attributable to shareholders was ¥40,892,532.15, up 23.54% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥28,536,287.99, reflecting a 41.85% increase year-over-year[6] - The company achieved a revenue of 1.419 billion RMB in the first three quarters of 2025, representing a year-on-year growth of 25.81%[17] - Revenue from drug development and commercialization services was 1.179 billion RMB, reflecting a year-on-year increase of 34.91%[17] - Total operating revenue for the current period reached ¥1,419,054,885.82, an increase of 25.7% compared to ¥1,127,892,555.29 in the previous period[24] - The net profit for the current period is CNY 113,390,631.27, a decrease of 13.9% compared to CNY 131,790,818.60 in the previous period[25] - The total profit for the current period is CNY 128,234,163.84, down from CNY 147,998,927.07 in the previous period[25] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥7,794,641,752.32, a 57.94% increase from the end of the previous year[6] - The company's equity attributable to shareholders increased by 139.29% to ¥7,149,000,685.97 compared to the end of the previous year[6] - Total liabilities decreased to ¥645,641,066.35 from ¥1,947,719,670.04, a decline of 66.9%[22] - Non-current assets increased to ¥5,131,662,934.01 from ¥2,218,334,497.16, reflecting a growth of 131.5%[21] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥543,482,604.71, a significant increase of 187.74%[6] - The net cash flow from operating activities was 543 million RMB, a significant increase of 187.74% compared to the same period last year[18] - The cash flow from investing activities shows a net outflow of CNY 307,707,118.32, compared to a smaller outflow of CNY 5,986,725.75 in the previous period[28] - The cash flow from financing activities resulted in a net outflow of CNY 247,171,819.29, an improvement from a net outflow of CNY 377,079,879.92 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,457[12] - The largest shareholder, Yang Minmin, holds 17.71% of the shares, amounting to 41,403,319 shares, with 12 million shares pledged[12] Cost Management - The company reported a 44.13% increase in operating costs, totaling ¥979,876,477.06 for the year-to-date[10] - Total operating costs amounted to ¥1,281,579,226.63, up 26.6% from ¥1,011,642,933.42 in the prior period[24] - The company reported a net profit margin improvement, with operating costs growing at a slower rate than revenue[24] - The company plans to maintain dynamic balance between cost control and strategic development to support long-term sustainable growth[17] Market and Business Development - New orders for CDMO services increased by 15% year-on-year, with new business orders for peptides and ADCs growing by over 100%[18] - The company is focusing on expanding its market presence and enhancing product development strategies moving forward[24] - The company is prioritizing resource allocation towards technology services and CMC business to strengthen long-term partnerships with core clients[17] Other Financial Metrics - The basic earnings per share for Q3 2025 was ¥0.2032, up 22.12% year-over-year[6] - Basic earnings per share decreased to 0.5635 from 0.6626 in the previous period[26] - The company experienced a foreign exchange impact of CNY 1,465,968.39 on cash and cash equivalents[28] - The company reported a significant increase in other income to CNY 16,262,839.51 from CNY 7,184,657.22 in the previous period[25] - The total comprehensive income for the current period is CNY 3,058,673,130.81, significantly higher than CNY 130,726,069.30 in the previous period[26]